“This is a major step forward for patients with obstructive sleep apnea.” Ute Grabowsky/Photothek via Getty The FDA conducted two studies, both of which found that Zepbound helps reduce ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity ... a treatment to reduce the risk of ...

The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and ... Wegovy to be used to reduce the risk of strokes, heart ...

Zepbound works for OSA by helping to reduce excess body weight ... later studies found that this weight loss can help treat sleep apnea that is linked with obesity. Zepbound can be an effective ...

23, 2024 -- The FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA ... OSA can reduce oxygen flow, disrupt heart rhythms ...

Lilly in April said Zepbound, known chemically as tirzepatide, helped reduce episodes of irregular breathing in patients with obstructive sleep apnea by 55% in the first study and by 62.8% in the ...

Share on Pinterest A clinical trial shows that Zepbound ... 2024 and found tirzepatide helps reduce symptom severity by almost two-thirds in adults with obesity and obstructive sleep apnea.

“This is a major step forward for patients with obstructive sleep apnea.” The FDA conducted two studies, both of which found that Zepbound helps reduce sleep apnea symptoms in some patients by ...

Dec. 21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.